Santiago Gisler,  —

Male patients with group 3 pulmonary hypertension (PH) have worse right ventricular (RV) function compared with female patients, according to a  study. Impaired RV function also was found to be associated with reduced overall survival and higher hospitalization rates linked to heart failure. The group study “Clinical Determinants and…

Doctors in the Netherlands are using the VMS Heart Analysis System, developed by Ventripoint Diagnostics, for early diagnosis of pulmonary hypertension (PH) in sarcoidosis patients. Approximately 500 patients with sarcoidosis have been tested, using the VMS Heart Analysis System for detecting PH at an early stage. Marco Post,…

Tracleer (bosentan) treatment improves mean pulmonary arterial pressure (mPAP) in β-thalassemia patients with potential pulmonary arterial hypertension (PAH), according to a case report of three patients. The report, “The improvement of pulmonary artery pressure after bosentan therapy in patients with β-thalassemia and Doppler-defined pulmonary arterial hypertension,”…

Higher levels of certain high-density lipoproteins (HDLs) improve the survival of pulmonary arterial hypertension (PAH) patients, according to a recent evaluation of two PAH patient cohorts. Targeting certain HDL subclasses may improve future PAH treatment. The study, “Reduced plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary…

Analytics 4 Life and Actelion Pharmaceuticals have announced a collaboration agreement to test CorVista as a potential cardiac imaging technology for the diagnosis of pulmonary hypertension (PH). CorVista is a non-invasive diagnostic application that uses Phase Space Tomography to measure cardiac patterns, and to discover irregularities…

Low diffusing capacity of the lung for carbon monoxide (DLCO) is a key indicator of mortality in group 3 pulmonary hypertension (PH), according to a study. The finding suggests a potential tool to asses patient risk based on DLCO outcomes. The study, “Survival in pulmonary hypertension due to chronic…

Biotechnology company Morphogen-IX recently announced that it will be further developing MGX292 as its treatment candidate for pulmonary arterial hypertension (PAH). The company’s decision is supported by previous preclinical studies that have shown the potential of MGX292, a signaling protein analogue, as a safe and effective therapy for PAH.

A receptor protein present in immune cells is a potential target for treating pulmonary hypertension (PH), according to a new study. The findings — based on patient lung tissue and animal experiments – showed a link between low levels of Toll-like receptor 3 (TLR3) and the disease. Published in the…